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Background: Venous leg ulcers, affecting approximately 1% of the population, are costly to manage due to poor
healing and high recurrence rates. We evaluated an evidence-informed leg ulcer care protocol with two frequently
used high compression systems: ‘four-layer bandage’ (4LB) and ‘short-stretch bandage’ (SSB).
Methods: We conducted a cost-effectiveness analysis using individual patient data from the Canadian Bandaging
Trial, a publicly funded, pragmatic, randomized trial evaluating high compression therapy with 4LB (n = 215) and SSB
(n = 209) for community care of venous leg ulcers. We estimated costs (in 2009–2010 Canadian dollars) from the
societal perspective and used a time horizon corresponding to each trial participant’s first year.
Results: Relative to SSB, 4LB was associated with an average 15 ulcer-free days gained, although the 95% confidence
interval [−32, 21 days] crossed zero, indicating no treatment difference; an average health benefit of 0.009 QALYs
gained [−0.019, 0.037] and overall, an average cost increase of $420 [$235, $739] (due to twice as many 4LB
bandages used); or equivalently, a cost of $46,667 per QALY gained. If decision makers are willing to pay from
$50,000 to $100,000 per QALY, the probability of 4LB being more cost effective increased from 51% to 63%.
Conclusions: Our findings differ from the emerging clinical and economic evidence that supports high compression
therapy with 4LB, and therefore suggest another perspective on high compression practice, namely when delivered
by trained registered nurses using an evidence-informed protocol, both 4LB and SSB systems offer comparable
effectiveness and value for money.
Trial registration: ClinicalTrials.gov Identifier: NCT00202267
Keywords: Randomized controlled trial, Cost-effectiveness, Leg ulcers, Compression therapy, Community careBackground
Community care of individuals with chronic wounds
is an important issue for community care authorities as
it consumes approximately 14% of their budget [1]. In
particular, budget shortfalls and nursing shortages make
caring for individuals with venous leg ulcers a challenge
[2]. This chronic condition affects approximately 1% of
people at some time in their lives [3]. It is associated with
poor healing [4], high recurrence [5], and negative impact
on physical and psychological wellbeing [6].* Correspondence: ba.pham@theta.utoronto.ca
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reproduction in any medium, provided the orBest practice supported by high level evidence
recommends high compression bandaging applied by
well-trained clinicians for individuals with leg ulcers
associated with venous insufficiency [7-11]. Compression
bandaging systems are all designed to improve venous
return but vary by construction (knitted, woven), com-
ponents (elastic, non-elastic), performance (long-stretch,
short-stretch) and layers (single-layer, multiple-layer)
[12]. Some frequently used systems are the “four-layer
bandage” system (strictly speaking a four-component
system, 4LB) and the multi-component compression
that includes a “short-stretch bandage” (SSB) [12]. The
Canadian Bandaging Trial (CBT, n = 424 participants),
funded by the Canadian Institutes of Health Research, was
a pragmatic, multi-centre (10 centres in three provinces),
open-label, randomized comparative trial evaluating thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy with 4LB and SSB for community care of venous
leg ulcers [13,14]. Results of the effectiveness analysis
have been recently published [13]. On average, leg ulcers
in participants treated with 4LB heal slightly faster
than those in SSB participants but overall, the treat-
ment groups are not significantly different with respect
to healing times, recurrence rates, health-related quality




This cost-effectiveness analysis compared the costs and
quality-adjusted life years (QALYs) of high compression
therapy with 4LB and SSB for individuals with venous
leg ulcers using individual patient data from the CBT.
The comparison was conducted within the following
decision-making context: community care setting (home
or nursing clinic); participating centres were supported
during the pilot phase of the trial to develop a common
evidence-informed protocol for venous leg ulcers (e.g.,
full assessment, ankle brachial pressure index to screen
for arterial disease) [14]; and registered nurses (RNs) with
the trial were trained on the evidence-informed protocol
to reduce variation in service delivery and bandaging
skills [13,14]. Ethics approval for the trial was received
from Queen’s University Research Ethics Board, Kingston
Canada (REB# NURS-140-03).
We conducted the analysis according to the intention-
to-treat principle [15]. Given the funding source, we esti-
mated costs from the societal perspective in the base case
analysis and given the decision-making context, consid-
ered the health systems and community care perspectives
in scenario analyses [16]. All costs are expressed in
2009–2010 Canadian dollars. We measured QALYs dur-
ing the first year of the trial and therefore did not use
discounting of future outcomes [16].
Patient population
The patient population is described elsewhere [13]. In
total, 424 consenting individuals referred for community
care with a venous leg ulcer were randomized to 4LB
(n = 215) and SSB (n = 209). In total, 23 (11%) 4LB parti-
cipants were lost to follow-up and 57 (27%) participants
discontinued therapy before healing. The corresponding
number for SSB participants was 10 (5%) and 44 (21%).
Reasons for lost to follow-up and discontinuation are
reported elsewhere [13]. Participants were on average
65 years of age, of whom 80% were fully mobile.
High compression therapy
In the late 1990’s, best practice recommendations in
Canada and elsewhere, supported by high level evidence,indicate that the most effective treatment for venous leg
ulcers is high compression bandaging [7,17-19] applied
by well-trained healthcare professionals [20]. By 2004
when the CBT trial started, high compression bandaging
had become the standard of care, although it was unclear
which high compression systems should be used in rou-
tine practice [21].
In the CBT, community care RNs trained in both
the 4LB and SSB systems administered the randomly
allocated high compression system to participants. The
4LB system is available as a kit (i.e., ProforeW, Smith &
Nephew Medical Ltd.) and is used once and discarded.
There is no pre-packaged SSB system. Instead, the
attending nurses selected the bandages (e.g., the initial
protective padding layer covered with two bandaging
layers) depending on a participant’s leg circumferences.
Whenever possible, SSB bandages (e.g., ComprilanW,
Beiersdorf-Jobst, Inc.) were washed by the participants
and reused.
Resources used
Resources utilization data were collected from baseline
to healing or 12 months whichever came first. In the
CBT, visit schedule (at least once a week) was not dic-
tated by the trial protocol but rather determined by the
visiting nurse. At each visit, nursing staff completed a
clinical sheet detailing the care given (e.g. dressings,
skin treatments), the approximate visit time, and also
documented on a supply log all newly opened sup-
plies provided by the community care authority (e.g.,
compression bandages, wound contact layers, cohesive
bandages).
Monthly and at the time of healing, participants filled
out expense forms for resources consumed or expenses
incurred because of leg ulcers, including health services
used (i.e., visits to hospitals, family physicians, specialists,
and emergency rooms), out-of-pocket expenses (i.e., taxi
fares, parking fees, and preventive supplies (e.g., stocking,
alternate shoes)), hire help (e.g., cleaning, meal prepar-
ation, gardening, and snow shovelling) and lost work
days.
We assumed that other resources unrelated to leg
ulcers had been unchanged with treatment allocation.
Unit costs
Table 1 displays unit costs of the resources used for leg
ulcer care. The site-specific unit costs of treatment sup-
plies were obtained from the participant centres. The
average cost of the 4LB kit was approximately $30 (range:
$23, $41). The cost of SSB depends on how the system
is assembled for a participant’s leg circumferences (e.g.,
6- and 8-centimeter bandages and padding). Its cost was
participant-dependent, ranging on average from $29 to
$35 (overall range: $20, $42).
Table 1 Unit prices used to value resources consumed
(2009–2010 Canadian dollar)
Item of resource Unit Unit cost ($) Source
High compression bandages
Four-layer bandage (4LB) system Kit 29.55 Site data*
Short-stretch bandage (SSB) system
6 cm bandage Each 11.69 Site data*
8 cm bandage Each 13.90 Site data*
10 cm bandage Each 14.89 Site data*
12 cm bandage Each 17.27 Site data*
Padding Each 2.91 Site data*
Typically used SSB system
6 cm+ 8 cm+padding System 28.50 Site data*
8 cm+ 10 cm+padding System 31.70 Site data*
10 cm+ 12 cm+padding System 35.07 Site data*
Hourly nursing wage Hour 35.15 ONA†
Health services utilization
Family doctor visit Visit 34.70 OHIP{
Specialist visit Visit 68.31 OHIP{
Emergency room visit Visit 252.00 OHIP{
Outpatient hospital visit Visit 426.00 OCCI}
Time cost of lost work due to
leg ulcer Hour 9.41 HRSD}
Abbreviations: ONA: Ontario Nursing Association. OCCI: Ontario Case Costing
Initiative. OHIP: Ontario Health Insurance Plan database. HRSD: Department
of Human Resources and Skills Development. Notes: *Unit prices are for
illustration purposes only; the analysis uses site-specific prices (see Methods).
†Average full-time hourly rate of an RN [22]. {Mean costs of physician services
from OHIP database (see Methods). }Average direct (and overhead) cost
of ambulatory care visits [25]. }Average minimum hourly wages across
provinces [26].
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[22]. Average unit costs for physician services (family
physicians, specialists, and emergency departments - EDs)
were obtained from the Ontario Health Insurance Plan
dataset [23]. A location code in the dataset indicates
whether the service was provided in a physician’s office
or in an ED. Costs reflect mean fee paid per visit (e.g.,
$52 for physician cost per ED visit). The total average
cost per ED visit includes an additional $200 for non-
physician costs [24]. The mean direct cost (including
overhead costs) of outpatient hospital (ambulatory care)
visits was obtained from the Ontario Case Costing Initia-
tive [25]. The time cost of lost work was valued using the
average minimum wage [26].Cost estimates
From the community care perspective, the costs of
nursing visits and all treatment supplies provided by the
community care authorities were included. The health
system costs included the community care costs and visit
costs to outpatient services, family physicians, specialistsand emergency rooms. The societal costs included the
health system costs and all expenses and lost income
related to leg ulcers incurred by the participants.
Quality-adjusted life-years
QALYs were derived for all participants to reflect sur-
vival time, treatment outcomes and health-related quality
of life according to the EQ-5D™ questionnaire [27]. The
EQ-5D™ is a generic measure of health status, where
health is characterised on five dimensions (mobility, self
care, ability to undertake usual activities, pain, anxiety /
depression) [28]. Each dimension has 3 levels, reflecting
“no health problems,” “moderate health problems,” and
“extreme health problems.” Each response placed a par-
ticipant into one of 243 mutually exclusive health states,
each of which has previously been valued on the 0
(equivalent to dead) to 1 (equivalent to good health)
‘utility’ scale to derive a health-related quality-of-life
weight from a sample of 4048 members of the US
public [29]. We used the US valuation scheme because
at the time of the analysis a Canadian scheme is still
under-development (Dr. Jeffrey A. Johnson, University
of Alberta, personal communication, April 3, 2010).
Participants filled out the EQ-5D™ questionnaire at
baseline, every three months while on treatment or at
healing time and 3 months post-healing. Over one year,
each participant had a quality-of-life weight from three
to five time-points and, by using area under the curve
methods which effectively weights time by health-related
quality of life, we derived QALYs [30]. To account
for baseline variation in quality-of-life weights, we esti-
mated mean QALYs for treatment groups adjusting for
baseline differences [31].
Data analysis
Scenario analyses were conducted by varying perspec-
tives to inform different decision makers. We presented
the results separately for societal, health system and com-
munity care perspectives. We conducted the base case
analysis using site-specific wholesale prices of all treat-
ment supplies, accounting for variation in the unit prices
of 4LB kits, and variation in the types of SSB band-
ages assembled according to individual participants’ leg
circumferences and their varied unit prices. Sensitivity
analyses were conducted 1) using average, low and high
prices of the 4LB kit and 2) using highest unit prices
(of the site-specific prices) of the bandages and padding
assembled for the SSB systems.
Relative to SSB, the average ulcer-free days gained with
4LB was estimated by the median difference in the time
to healing using the Kaplan-Meier method [15]. The
mean costs and mean QALYs of 4LB and SSB were esti-
mated using methods to adjust for censored data due to
lost to follow-up [32-34]. Patients who discontinued their
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were included in the analysis, conducted according to the
intention-to-treat principle [15]. We estimated the dif-
ferential mean costs and mean QALYs of 4LB relative
to SSB, and derived the corresponding incremental cost
effectiveness ratios (ICERs).
To account for sampling variation, we re-sampled the
individual participant data from the original CBT with
replacement to create 1000 bootstrapped CBT trials and
re-analyzed the bootstrapped trial data [35,36]. For sim-
plicity, we did not take into account variation in the unit
costs of health services used and hourly wages (Table 1).
We derived the 95% “credible” (hereafter “confidence”)
intervals for differential costs and QALYs using the bias
corrected and accelerated bootstrap method [35]. We
plotted cost effectiveness acceptability curves [37,38],
showing the probability that 4LB is more cost effective
than SSB for different values decision makers are willing
to pay for an additional QALY gained with compression
therapy.
All analyses were conducted in R, version 2.9.0,
R Foundation for Statistical Computing.Table 3 Mean costs during the first year of follow-up




Table 2 summarizes resources used and time loss due
to leg ulcers. Relative to SSB, 4LB was associated with a
14% decrease in the average number of nursing visits and
average total nursing time. On average, participants used
approximately twice as many 4LB as SSB bandages. 4LB
participants visited outpatient services, family physicians,
specialists and emergency rooms less often than SSB par-
ticipants, although the annual utilization rates were veryTable 2 Resources used and time loss due to leg ulcers
during the first year of follow-up
4LB (n= 215) SSB (n = 209) Difference*
Mean (SD) Mean (SD)
Number of nursing visits 28.25 (24.16) 32.64 (24.07) −14%
Total nursing time (hour) 15.90 (13.28) 18.48 (15.63) −14%
Total number of
bandages used 24.04 (24.54) 11.64 (10.07) 107%
Health services used
Family doctor visits† 0.284 (0.790) 0.368 (0.857) −23%
Specialist visits† 0.019 (0.135) 0.081 (0.402) −77%
Hospital visits† 0.005 (0.068) 0.014 (0.119) −64%
Emergency room visits† 0.260 (0.087) 0.411 (1.603) −37%
Lost work hours{ 1.14 (6.09) 1.24 (5.29) −8%
Abbreviations: 4LB: four-layer bandage. SSB: short-stretch bandage. SD:
standard deviation. Notes: *(4LB mean - SSB mean), expressed as percentages
of the SSB mean. †Total number of visits per participant. {Total number of
hours missed work due to leg ulcer per participant.small. There were no reported hospitalizations and the
mean numbers of lost work hours were very small.
Costs
Table 3 shows mean costs per participant. The marked
differences were in high compression bandaging cost ($606
more with 4LB, because twice as many 4LB bandages
were used), nursing time cost ($90 less with 4LB, mainly
due to the average ulcer-free days gained with 4LB,
as reported below), and out-of-pocket expenses ($30 less
with 4LB). Overall, 4LB cost more per participant per
year (point estimate: $420; 95% confidence interval:
$235 to $739).
In summary, bandaging costs were substantially higher
for 4LB and these were only partially offset by the lower
health utilisation costs for 4LB compared with SSB.
Health outcomes
Table 4 summarizes healing time and QALYs. Leg ulcers
treated with 4LB on average healed slightly faster than
those with SSB, resulting in an average 15 ulcer-free days
gained with 4LB; however, the 95% confidence interval
(−32 days, 21 days) crossed zero, indicating no statisti-
cally significant difference between treatment groups.
Healing rates were also not different between treatments:
at 12 weeks, the healing rate was 58% for 4LB and 53%
for SSB; the corresponding rate was 71% and 78% at
26 weeks and 83% and 92% at 52 weeks (data not shown).
The mean quality-of-life weights were comparable





Nursing visits 563 (463) 653 (547) −90
Compression
bandages 811 (897) 205 (232) 606
Health services
used† 35 (96) 46 (117) −11
Out-of-pocket
expenses{ 28 (78) 58 (177) −30
Lost work due to
leg ulcers 1.82 (8.08) 2.39 (9.06) −0.57
Hired help} 0.43 (3.25) 0.56 (2.98) −0.13
Mean (95% CI) Mean (95% CI)
Total cost 1570 (1448, 1870) 1150 (1014, 1297)
Differential cost 420 (235, 739 )
Abbreviations: 4LB: four-layer bandage. SSB: short-stretch bandage.
SD: standard deviation. CI: confidence intervals derived from the 1000
bootstrapped trials. Notes: *(4LB mean – SSB mean). †Per participant costs of
visits to family physicians, specialists, outpatient services, and emergency
rooms. {Per participant expenses related to leg ulcer care. }Costs of hired help
related to leg ulcer.
Table 4 Summary of healing time and QALYs during the
first year of follow-up
4LB (n= 215) SSB (n = 209)
Median (95% CI) Median (95% CI)
Healing time (days) 62 (51, 73) 77 (63, 91)
Ulcer-free days −15 (−32, 21)
Mean (95% CI) Mean (95% CI)
Quality-adjusted life years 0.839 (0.811, 0.862) 0.830 (0.809, 0.851)
Difference (QALYs) 0.009 (−0.019, 0.037 )
Abbreviations: 4LB: four-layer bandage. SSB: short-stretch bandage.
CI: confidence interval derived from the 1000 bootstrapped samples.
QALY: Quality-adjusted life year.
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Both groups attained similar improvement in quality-
of-life weights at healing and sustained the improvement
comparably at 3 months post healing (Figure 1, broken
lines), partially reflecting similar recurrence rates (10%
for 4LB and 13% for SSB at 52 weeks, data not shown).
Comparable trends in health-related quality of life
between groups were also observed with the physical
and mental components of the SF-12 (data not shown).
Partially due to the average 15 ulcer-free days gained
with 4LB, 4LB was associated with a differential mean
of 0.009 QALYs (95% confidence interval: -0.019, 0.037
QALYs, Table 4), corresponding to 3.3 quality-adjusted
life-days gained (−7.0, 13.5).
Cost effectiveness
For the base case analysis, both mean overall costs
and mean QALYs were higher for 4LB than for SSBFigure 1 Mean quality of life weights* by treatment group
during the first year of follow-up. Abbreviations: 4LB: four-layer
bandage. SSB: short-stretch bandage. Notes: Error bars denote
standard error of the means. *Health-related quality of life according
to the EQ-5D™ questionnaire [27].participants, with mean differences of $420 and 0.009
QALYs. Here, the issue is whether decision makers are
willing to pay $420 more for the 0.009 QALYs gained, or
equivalently, the additional cost of $46,667 ($420/0.009)
per QALY gained associated with 4LB — the implied ICER.
Using a willingness-to-pay value of $50,000 per QALY
as an exchange rate, the health benefit of 0.009 QALYs
gained is equivalent to $450 and the net monetary benefit
associated with 4LB was $30 ($450 - $420). Alternatively,
the additional cost of $420 is equivalent to 3.1 quality-
adjusted life days and the net health benefit was 0.2
(approximately 3.3 – 3.1) quality-adjusted life days. At
a willingness-to-pay value of $100,000 per QALY, the
corresponding net monetary benefit was $480 and the
corresponding net health benefit was 1.8 quality-adjusted
life days.
Above, the ICER was estimated with sampling uncer-
tainty, which is represented in Figure 2 in the form of a
cost effectiveness acceptability curve. The curve indicates
that the higher the value decision makers are willing to
pay for an additional QALY gained, the higher the prob-
ability that 4LB will be more cost effective than SSB.
For willingness-to-pay values ranging from $50,000 to
$100,000 per QALY gained, the probability that 4LB is
more cost effective than SSB increased from 51% to 63%.
Scenario and sensitivity analyses
Table 5 displays results of the scenario and sensitiv-
ity analyses. The ICER was approximately $48,000 from
a health system perspective and approximately $51,000
from a community care perspective. When the unit price
of the 4LB kit was fixed at its average ($30), lowest ($23)
and highest ($39) price, the ICERs changed slightly fromFigure 2 Probability of 4LB being more cost-effective at
different willingness-to-pay values. Abbreviations: 4LB: four-layer
bandage. SSB: short-stretch bandage.
Table 5 Results of base case, scenario and sensitivity analyses*
4LB (n= 215) SSB (n = 209) Differential cost Cost per QALY gained
Mean cost (95% CI) Mean cost (95% CI) Mean (95% CI)
Base case analysis{ 1570 (1448, 1870) 1150 (1014, 1297) 420 (235, 739 ) 46,667
Scenario analyses
Community care perspective 1497 (1371, 1760) 1034 (930, 1169) 463 (308, 748) 51,444
Healthcare payer perspective 1519 (1394, 1786) 1089 (968, 1216) 430 (2801, 749) 47,777
Sensitivity analyses
Unit price of a 4LB kit
Average ($29.55)† 1567 (1442,1879) 1150 (1014, 1297 ) 417 (256, 753) 46,333
Low ($22.70)† 1561 (1433, 1849 ) 1150 (1014, 1297 ) 410 (251, 742) 45,556
High ($39.10)† 1576 (1459,1864) 1150 (1014, 1297 ) 426 (246, 754) 47,333
Highest prices of SSB systems 1570 (1448, 1870) 1169 (1035, 1315) 401 (240, 729) 44,556
Abbreviations: 4LB: four-layer bandage. SSB: short-stretch bandage. CI: confidence interval. Notes: *Only mean costs are displayed in Table 5; refer to Table 4 for
mean QALYs. {According to the societal perspective. †Average costs of the 4LB kit from site-specific prices.
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prices of the components of the SSB systems (instead
of the site-specific unit prices of the components), the
ICER was approximately $45,000.
Discussion
We evaluated the cost-effectiveness of high compression
therapy for community care of individuals with venous
leg ulcers. The effects of the two high compression sys-
tems were similar. Relative to the SSB system, the 4LB
system was associated with a very small health benefit
(approximately 3 quality-adjusted life-days gained over
one year), and with a small cost increase (an average
increase of $420 per individual per year), or equivalently,
a cost of approximately $47,000 per QALY gained. For
willingness-to-pay values between $50,000 and $100,000
per QALY, the probability that 4LB is more cost effective
than SSB ranged from 51% to 63%, indicating that the
decision about value for money is finely balanced. Our
results are different from recently published studies and
therefore suggest another perspective on high compres-
sion practice.
Existing clinical and economic evidence supports
high compression therapy with 4LB for venous leg ulcers.
Results from a meta-analysis including individual patient
data from 90% of known randomized patients (or 5 trials)
show that relative to SSB, 4LB is associated with signifi-
cantly shorter healing time of approximately 30% and
the treatment effect is consistent across patients with dif-
ferent prognostic profiles [39]. Similar results are also
reported in a related Cochrane systematic review (6 ran-
domized trials, a total of 847 participants), but care set-
ting remains an important factor for variation in clinical
outcomes [40]. A cost-effectiveness analysis using indi-
vidual patient data from the largest trial in the review
[41], the VenUS I randomized trial (n = 387 participants)also shows that 4LB is more effective and less costly than
SSB for community care of venous leg ulcers in the UK
[42]. On the other hand, results from the CBT (424 parti-
cipants) show that in the practice context of trained RNs
using an evidence-informed protocol, the choice of high
compression bandage system does not materially affect
healing times, recurrence rates, health-related quality of
life, or pain [13]. Using CBT data, our results show that
SSB is as economically attractive as 4LB. Within the right
organization of care, the choice of high compression ban-
daging systems appears to be less important. If delivery
of only one, or the other, is possible because of local
factors and resources, the CBT results suggest that the
expected health benefits and costs would not be com-
promised whichever is selected.
O’Meara et al. conducted a systematic review (and
meta-analysis of randomised controlled trials with data
from individual patients) evaluating 4LB and SSB for
venous leg ulcers [39]. They identified seven eligible trials
(887 patients, and patient level data were retrieved for
5 trials, including 797 patients) and reported that 4LB
was associated with significantly shorter time to healing:
adjusted hazard ratio 1.31 (95% confidence interval: 1.09
to 1.58). The CBT increases the information available by
approximately 50%. Adding the CBT data to the existing
evidence in a meta-analysis conducted by CBT members
(Drs. Andrea Nelson and Margaret Harrison, Journal of
Community Nursing, manuscript submitted), the hazard
ratio estimate is 1.14 (0.98, 1.32). The updated evidence
suggests that high compression is the key to venous leg
ulcer care and the method of delivery is less important
than indicated in some earlier work [39-42].
Limitations
There are a number of important limitations. First, the
CBT was open-labelled. Blinding the nurse to the
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were applied it would have been excessively intrusive
to remove them solely for the purpose of an outcome
assessment [13]. Healing assessment however was vali-
dated by photos assessed by an expert who was located
remotely from the site of care and blinded to treatment
allocation [13]. We expected minimal bias potentially
introduced by the open-label manoeuvre since i) the
primary analysis was based upon time to healing and
ii) the choice of bandage system did not seem to materi-
ally affect healing times, recurrence rates, health-related
quality of life, or pain [13].
In mid 2011, we analyzed our EQ-5D data using prefer-
ence values of EQ-5D health states derived for the US
public [29]. In February 2012, the preference valuation
for the Canadian public became available [43]. According
to Bansback et al. 2012, the correlation between the US
and Canadian tariffs is high (i.e., 0.96), although the max-
imum absolute difference could be large (i.e., 0.06).
This is primarily because i) compared to US participants,
Canadian participants revealed lower preference values
for severe health states and ii) different transformations
were applied to values of worse-than-dead states (a linear
and monotonic transformation was used for the US and
Canadian valuation, respectively so that these values are
bounded between −1 and 0). While these are important
measurement issues, they would be far less important for
the average results in our cost-effectiveness analysis. This
was partially because CBT participants 1) were relatively
young (i.e., 65 years of age, relative to for example,
approximately 71 for a similar trial, the VenUS I trial),
2) were relatively mobile (i.e., 80% relative to 61%
for VenUS I), and 3) were with relatively high average
EQ-5D valuation at baseline (i.e., 0.77 versus 0.60 for
VenUS I) [41,42]. In addition, because the health-related
quality of life profiles (i.e., EQ-5D, SF-12 mental and
physical component scores) were not markedly different
between treatment groups, we did not anticipate any
major impacts of this limitation on the results of our
analysis.
We valued collected resources that were deemed attri-
butable to leg ulcers, according to the participants. We
did not assess the reliability of this attribution although
according to our collective experience with conducting
the VenUS I and CBT trials, participants would recall
most high-value items associated with their leg ulcers.
Last but not least, we only evaluated two frequently
used high compression systems (4LB and SSB) although
there are a large number of systems available, including
newer systems [12].
Conclusions
Our findings differ from the emerging clinical and eco-
nomic evidence that supports high compression therapywith 4LB, and therefore suggest another perspective on
high compression practice. Namely when delivered by
trained registered nurses using an evidence-informed
protocol, both 4LB and SSB bandages offer comparable
effectiveness and value for money.
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